This study thoroughly examines the following markets: orphan diseases, Gaucher's Disease and Pulmonary Arterial Hypertension (PAH) markets in Europe.
该项研究通过调查以下市场：孤儿疾病，高歇病和欧洲的肺动脉高压（PAH）市场。
The causes of these disorders are unknown, and both are considered orphan diseases because they each affect less than 200,000 people in the United States.
由于这两种疾病在美国的患病人群均少于20万，因此都被认为是罕见病。
They conclude that single patient trials can be a logical approach to identifying potentially beneficial drugs, especially in the case of rare or orphan diseases.
他们认为通过对单个病人的试验能够有逻辑性的辨识药物的潜在益处，尤其在稀有罕见病例中。
The European orphan diseases market grapples with numerous challenges. Of these, the most serious are the lack of awareness, poor diagnosis and limited accessibility of orphan drugs.
欧洲孤儿疾病市场存在许多问题。其中，最严重的是缺乏认识，不良的诊断和有限利用孤儿药物。
Many parasitic, tropical, and "orphan" diseases are infrequent in the developed world, the primary source of revenue for medicines manufacturers.
许多寄生虫病、热带病和“罕见”病在作为药品制造商主要收入来源的发达世界很少见。
Ten are for rare or “orphan” diseases, which frequently lack any therapy because of the small number of patients with the condition, such as a treatment for hereditary angioedema;
十种药是为罕见或“孤儿”病，因为患者少的情况经常缺乏任何治疗，例如遗传性血管水肿治疗。
Orphan drugs are either drug or biologic products used to treat diseases or conditions affecting fewer than 200,000 people in the United States.
孤儿药物包括药物或者生物制品，用于治疗疾病，并且在美国发病人数少于20万人。
Orphan drugs are either drug or biologic products used to treat diseases or conditions affecting fewer than 200,000 people in the United States.
孤儿药物包括药物或者生物制品，用于治疗疾病，并且在美国发病人数少于20万人。
应用推荐